Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.

[1]  G. Garcia-Manero,et al.  Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response , 2015, European journal of haematology.

[2]  J. C. Williamson,et al.  Current pathology practices in and barriers to MDS diagnosis. , 2013, Leukemia research.

[3]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[4]  M. Cazzola,et al.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. , 2013, Blood.

[5]  A. A. van de Loosdrecht,et al.  Cutting edge: flow cytometry in myelodysplastic syndromes. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  M. Béné,et al.  Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes , 2013, Leukemia.

[7]  T. Haferlach,et al.  Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics , 2013, Haematologica.

[8]  J. Vardiman.  The classification of MDS: from FAB to WHO and beyond. , 2012, Leukemia research.

[9]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[10]  C. Pascutto,et al.  Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study , 2012, Haematologica.

[11]  C. Steidl,et al.  New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Órfão,et al.  Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group , 2012, Leukemia.

[13]  M. Loken,et al.  Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopenias , 2011, Cytometry. Part B, Clinical cytometry.

[14]  T. Haferlach,et al.  Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome , 2010, Cancer.

[15]  C. Lassen,et al.  Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells. , 2010, Cancer genetics and cytogenetics.

[16]  B. Smith,et al.  The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: a prospective study. , 2009, Leukemia research.

[17]  L. Malcovati,et al.  Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study , 2009, Haematologica.

[18]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[19]  P. Valent,et al.  Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions , 2009, European journal of clinical investigation.

[20]  Olga Pozdnyakova,et al.  Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. , 2008, Leukemia research.

[21]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[22]  J. Bennett,et al.  Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. , 2007, Leukemia research.

[23]  T. Haferlach,et al.  Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. , 2007, Leukemia research.

[24]  H. Deeg,et al.  Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. , 2003, Blood.

[25]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[26]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[27]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.